arrow
F

Federica Matteucci

IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
H指数:24
被引数:1,890

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world use of [18 F]fluorocholine PET/CT as a second-level imaging modality in primary hyperparathyroidism: a two-center observational study

[18F]氟代胆碱PET/CT作为原发性甲状旁腺功能亢进症二级影像学检查方法在真实世界中的应用:一项多中心观察性研究

2026-08-310
OA
Post-VABB Cavity-Targeted Avidin-Pretargeted [90Y]Y-DOTA-Biotin in Nonpalpable Breast Cancer: A Phase I Activity-Escalation Study (ARTHE)

术后VABB腔内靶向亲和素预靶向[90Y]Y-DOTA-生物素在非可触及乳腺癌中的应用:一项I期剂量递增研究(ARTHE)

Cancers
IF4.4
2026-08-280
OA
Radiopsy: a prospective observational study on quantitative multiparametric whole-body magnetic resonance imaging to discriminate between smoldering and multiple myeloma

Radiopsy:一项关于定量多参数全身磁共振成像以区分冒烟型骨髓瘤和多发myeloma的前瞻性观察研究

2025-12-011
OAAI
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study

177Lu-PSMA-617放射性配体疗法的疗效、毒性和临床结局:一项前瞻性、单臂、II期研究,研究对象为每周期接受5.5 GBq剂量的晚期去势抵抗性前列腺癌患者

2025-11-270
OAAI
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients
2024-08-290
OAAI
Advances in drug design and therapeutic potential of selective or multitarget 5-HT1A receptor ligands

选择性或多靶点5-HT1A受体配体的药物设计和治疗潜力研究进展

2024-05-291
PRE
Radioligand therapies in cancer: mapping the educational landscape in Europe
2023-04-142
OAAI
Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study
2023-03-0710
PRE
ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study
2022-01-132
OAAI